Introduction
Normal tissue growth involves a complex interaction of cell proliferation, hypertrophy, migration, differentiation and senescence which proceeds within strict temporal and anatomical constraints. While classical endocrine hormones such as growth hormone and thyroxine can influence the overall rate of growth and maturation they do not contribute to the fundamental intercellular signalling within tissues that underlies these processes. This appears to be the primary role of peptide growth factors. During the rapid development of the embryo and fetus peptide growth factors are associated with tissue induction, the clonal growth of stem-cell populations, and the appearance of differentiated function in the presumptive organs. In post-natal life the actions of growth factors are less obvious although notable exceptions demonstrate that the same biological pathways exist; the best studied examples are the role of somatomedins during longitudinal skeletal growth and the coordinated actions of several growth factors within the ovarian cycle, during testicular function, and during peripheral wound healing. The aim of this article is to present a broad overview of the diverse presence and actions of peptide growth factors during human development and reproduction.
Physical form and anatomical location
Those peptide growth factors that have been best characterized are shown in Table 1 . They are typically proteins of molecular weight < 30 000 which are synthesized and act within the local tissue environment as paracrine or autocrine hormones. Unlike classical endocrine hormones each growth factor may be synthesized by many anatomically diffuse tissues. They are not stored intracellularly in granules and release is largely dependent on de-novo synthesis. While acute release is not common this has been overcome during wound healing by the rapid delivery of several growth factors to the sites of tissue damage by platelet lysis. Peptide growth factors interact with receptors located on the cell membrane which are usually glycoproteins and which communicate with secondary messenger systems by conformational changes. This often involves the autophosphorylation of tyrosine residues located on the intracellular domain of the receptor. The second messenger systems utilized are diverse and include changes to intracellular calcium levels, cyclic AMP, cellular alkalization, and phosphoinositol metabolites. The net biological events induced by growth factors are, however, remarkably consistent and include a rapid stimulation of amino acid transport, glucose uptake and utilization, and RNA and protein synthesis. For many, but not all, growth factors this is followed by DNA synthesis and cell replication. The somatomedins or insulin-like growth factors (IGFs) are single chain polypeptides of Mr~7 500 which share structural and functional similarities with insulin. Two peptide species exist; IGF-I which has 70 amino acids and is encoded by a gene on human chromosome 12, and IGF-II which has 67 amino acids and derives from a gene on the short arm of chromosome 11 (Tricoli et ai, 1984 (Engstrom et ai, 1987; Rolfe et ai, 1988) . In the rat embryo mRNA for IGF-II was localized by cDNA/mRNA in-situ hybridization to yolk sac, hepatic bud, branchial arch mesoderm, and dermato-myotome between 10-5 and 14-5 days of gestation, and was additionally present in differentiated muscle, perichondrium, chondrocytes and gut epithelium in later gestation (Beck et ai, 1987) . In the human fetus in the early second trimester, IGFs were localized by immunohistochemistry to epithelia within the gut, kidney and lung; hepatocytes, adrenal cortical cells from the fetal zone, differentiated skeletal and cardiac muscle fibres, haemopoietic tissue and dermal skin (Han et ai, 1987b) . This distribution may depend on an association with specific IGF binding proteins which share a similar cellular distribution (Hill et ai, 1988) . The binding proteins may contribute to a sequestration of IGF peptides within certain cell populations, since analysis of IGF-I and -II mRNA distribution in human fetal tissues by in-situ hybridization suggested that the majority was present in fibrous mesenchymal tissues adjacent to the cell types positive for IGF peptides (Han et ai, 1987a) .
In post-natal life IGF peptide presence is less apparent in many tissues by immunohisto¬ chemistry compared to the fetus, but can be re-expressed when local damage is inflicted on skeletal muscle, vascular endothelium, hyaline cartilage or peripheral nerves (Hansson et ai, 1986 (Hansson et ai, , 1987 Jennische & Oliverecrone, 1987) . However, a strong expression of IGF peptides is retained in those tissues which continue to undergo rapid growth and differentiation, including the epiphyseal growth plate cartilage, testis and ovary. Within the cartilage growth plates of the long bones IGF-I is synthesized by proliferative chondrocytes but this ceases once cells have hypertrophied and become post-mitotic before matrix calcification (Isaksson et ai, 1987) . The expression of IGF-I within growth plate cartilage is largely dependent on the presence of growth hormone. IGF-I is likely to act as a paracrine or autocrine agent within growth plate cartilage to promote the clonai expansion of newly-formed chondrocytes and their subsequent differentiation. Within the rat testis IGF-I is released from Sertoli cells and is also located within spermatocytes (Andersson et ai, 1986; Smith et ai, 1987) . In the rat ovary IGF-I mRNA has been localized by in-situ hybridization to the granulosa cells surrounding the follicles, expression being greatest around the dominant follicles (Oliver et ai, 1988) . Human follicular fluid is a rich source of IGF-I which, in cohort follicles, correlates with that in the circulation. Concentrations are greatest in the dominant follicles and increase further following the LH surge, after which they correlate positively with oestrogen con¬ centrations (Eden et ai, 1988) . IGF-I is released by isolated rat granulosa cells, this being enhanced by GH or FSH and further augmented by oestradiol (Hsu & Hammond, 1987) .
Epidermal growth factor (EGF) is a single chain polypeptide of 53 amino acids with molecular weight of 6000. Mouse EGF was first isolated from male submaxillary glands and the equivalent human peptide, urogastrone, from urine (Cohen, 1962; Gregory, 1975) . A structural analogue of EGF is transforming growth factor-(TGF-a). This has a molecular weight of 7500 and shows a (Adamson & Meek, 1984) . It is unclear whether the peptide that might activate these receptors is EGF or TGF-. Although TGF-a was detected in the mouse embryo with the highest levels on Day 7 of gestation, in-situ hybridization studies in rats suggested that the embryo does not express TGF-at this time (Han et ai, 1987c) . However, abundant TGF-mRNA was present in maternal decidua, especially adjacent to the embryo. Decidual expression appeared after implantation, peaked at Day 8 and slowly declined to Day 15 in parallel with decidual résorption. Peak levels of TGF-may therefore be available to the embryo from a maternal source during gastrulation and neurulation. Early in the second trimester, EGF is present in the human fetus within cells at the base of the gastric and pyloric glands in the stomach, the Brunner's glands in the duodenum, the epithelium of the distal convoluted kidney tubules, anterior pituitary, pseudostratified columnar epithelium ofthe trachea and the placenta (Kasselberg et ai, 1985) . In post-natal life also, EGF is detectable by immunohistochemistry in association with epithelial layers demonstrat¬ ing rapid turnover, such as in gut and skin. Additionally, it is stored in large quantities in platelets and released during tissue injury. Similarly, its presence within monocytes may be related to wound healing.
Fibroblast growth factor (FGF) has been isolated from bovine pituitary and brain in both an acidic (pi 4-5) and basic (pi 9-6) form, each being of MT~1 6 000-17 000 (Gospodarowicz et ai, 1984; Esch et ai, 1985) . FGFs are potent mitogens for tissues derived from mesenchyme or neuroectoderm such as chondrocytes, fibroblasts, myoblasts, glial cells, adrenal cortex and ovarian granulosa cells (Gospodarowicz et ai, 1987) . They are the most effective mitogens so far identified for vascular endothelial cells, and additionally promote cell migration, invasion and the production of plasminogen activator; all necessary features of angiogenesis in vivo. FGF mRNA is detect¬ able in the Xenopus blastula (Kimelman & Kirschner, 1987) while the peptides are present in chick embryo brain, retina and vitreum from Day 11 of gestation. In adult life FGF is diversely distributed among tissues including ovary, adrenal, kidney and the anterior pituitary.
Platelet-derived growth factor (PDGF) was first identified within the storage granules of platelets. Human PDGF is a highly basic glycoprotein (pi 10-2) with two biologically equipotent variants, PDGF 1 which contains 7% carbohydrate and has a molecular weight of 31 000, and PDGF 2 with 4% carbohydrate and molecular weight 28 000 . In platelets both forms contain an -chain of 15 000-17 000 and a B-chain of 14 000 linked by disulphide bridges. The B-chain of PDGF shows extensive sequence homology with the viral p28 protein encoded by the v-sis oncogene (Waterfield et ai, 1983) , and the cellular sis gene was subsequently shown to encode the precursor protein for PDGF B-chain (Johnsson et ai, 1984) . In tissues other than platelets PDGF usually consists of a homodimer of two B-chains. PDGF stimulates prolifer¬ ation in many cell types derived from mesoderm including fibroblasts, smooth muscle cells, glial cells and ovarian granulosa cells . Goustin et ai (1985) found expression of PDGF in human placenta from as early as 21 days after conception. By in-situ hybridization the expression of the c-sis gene was localized to trophoblasts. Expiants of first trimester placenta released radioreceptor-assayable PDGF, while cultured trophoblast cell lines were rich in high affinity PDGF receptors, and responded to exogenous PDGF with an increased expression of the proto-oncogene c-myc accompanied by DNA synthesis. Since the expression of c-myc, which encodes a DNA binding protein and is one of the first intracellular events to take place following interaction of PDGF with its receptor, was also localized to trophoblasts this may represent an autocrine action of PDGF on trophoblast prolifer¬ ation during the early invasive growth ofthe placenta. In later fetal development mRNA for PDGF was identified in the human kidney (Fraizer et ai, 1987) . While PDGF continues to be present in aortic smooth muscle in the immature rat, expression in later life appears to be limited, in normal circumstances, to platelets where it contributes to wound healing following platelet lysis.
Transforming growth factor ß (TGF-ß) differs from the other growth factors outlined in that it predominantly acts as an inhibitor of cell proliferation. It is a homodimer of Mr 25 000 found in abundance in, and purified from, platelets. TGF-ß is a potent inhibitor of epithelial cell replication in vitro at picomolar concentrations (Strain et ai, 1986) . For mesodermal cells it can act as a bifunctional growth regulator, either enhancing the actions of other growth factors on cell repli¬ cation or serving as a growth inhibitor depending on the cellular substratum, the age of develop¬ ment of the tissue, and whether the cells are virally transformed (Roberts et ai, 1985) . TGF-ß stimulates fibronectin and collagen release, major constituents of extracellular matrix, by some fibroblast types; increases the release of plasminogen activator from other fibroblasts leading to a degradation of extracellular matrix glycoproteins; and modulates cell adhesion molecule receptors. These properties suggest a potential role in tissue modelling and this is supported by the anatomical distribution of TGF-ß in the embryo and fetus.
TGF-ß mRNA was found in the vegetal pole ectoderm of Xenopus embryos and is transcribed by a maternally-derived gene Vgl (Weeks & Melton, 1987 ). An ectodermal cell line, XTC, obtained from a metamorphosing tadpole releases a TGF-ß-like peptide in vitro (Rosa et ai, 1988) . In the 11-18-day mouse embryo TGF-ß has been localized immunohistochemically to differentiated and undifferentiated mesenchyme including bone and connective tissues, particularly that derived from neural crest such as palate, larynx, facial mesenchyme and teeth (Heine et ai, 1987) . Staining was most intense around sites of tissue morphogenesis involving mesodermal interaction with adjacent epithelia, including hair follicles, teeth and secondary palate. In late fetal rat development TGF-ß bioactivity was identified in multiple tissues, levels being greatest in muscle, lung, liver and kidney (Hill et ai, 1986) , while TGF-ß was released by isolated fetal rat calvaría and by myoblasts (Centrella & Canalis, 1985; Hill et ai, 1986) . After birth, TGF-ß concentrations in rat tissues decline rapidly to barely detectable levels (Hill et ai, 1986) , although in the human TGF-ß remains widely distributed amongst cells ofthe immune system including monocytes and T-lymphocytes. It has been proposed that its presence in the latter constitutes an autocrine negative feedback system on the clonai expansion of lymphocytes in response to interleukin 2 (Kehrl et ai, 1986 The ability of BALB/c-3T3 cells to traverse the cell cycle in growth factor-supplemented medium was dependent on the availability of amino acids, especially those in group such as cysteine, isoleucine, lysine, phenylalanine and tyrosine (Cooper & Wharton, 1985) . In medium deficient in amino acids cells become arrested at a point midway through Gj coincident with the time from which IGF-I is necessary. An additional amino acid-dependent restriction point was found in human fibroblasts 2-3 h before the G,/S boundary coincident with the completion of DNA-synthesizing enzyme transcription. This suggests that two periods within Gt in particular require protein synthesis and that both may be dependent on IGF-I.
This model of growth factor action during BALB/c-3T3 cell proliferation does not hold true for all cell types although the concept on 'competence' and 'progression' factors appears to be universal. Human fibroblasts have a greater endogenous ability to release IGFs in vitro than do the embryonic mouse fibroblasts (Clemmons et ai, 1981) . Consequently, this obviates the absolute need for IGFs during the G! phase. Additionally, PDGF is necessary throughout G! as well as at the Gq/G, interface for optimal proliferation to occur (Clemmons et ai, 1986) . Exogenous binding protein enhanced the mitogenic capacity of IGF-I on adult human fibroblasts, while other closely related species, also isolated from amniotic fluid, did not associate with cell membranes and antagonized IGF-I biologi¬ cal activity (Elgin et ai, 1987 (Slack et al., 1987) . TGF-ß also induced mesoderm formation in Xenopus ectoderm, especially muscle which was identified by the presence of a-actin mRNA (Rosa et ai, 1988) . A synergism existed between FGF and TGF-ß in this respect (Kimelman & Kirschner, 1987) . The most potent natural source of mesoderm-inducing activity is conditioned medium from Xenopus XTC cell cultures, a known source of TGF-ß. The ability of TGF-ß antiserum to block the mesoderm-inductive capacity of XTC-conditioned medium suggests that an amphibian TGF-ß may be the major bioactive moiety (Rosa et ai, 1988 A well-studied model of tissue differentiation in vitro is the fusion of myoblasts into polynuclear, post-mitotic myotubes. This process can be quantitated by measuring the rise in myotube-associated enzymes such as myokinase and creatinine phosphokinase, or the acquisition of acetyl choline receptors. Muscle differentiation largely occurs in utero in man but can still be observed in the first week post partum in the rat. Physiological concentrations of IGF-I or pharmacological concen¬ trations of insulin promoted the proliferation of newly isolated myoblasts and of established myoblast cell lines (Ewton & Florini, 1980; Hill et ai, 1985) . However, after 1 or 2 replicative cycles myoblasts ceased to proliferate in response to IGF-I and were instead stimulated to differentiate terminally (Ewton & Florini, 1981) . This action of IGF-I on myoblast differentiation was still apparent when proliferation was abolished by exposure of cells to cytosine arabinoside. Primary and established myoblast cultures also proliferated in response to FGF. However, FGF inhibited myoblast differentiation to maintain an expanding population of cells (Linkhardt et ai, 1981) . TGF-ß exerted rapid anabolic actions on isolated myoblasts, such as an increase in amino acid transport, but had little effect on myoblast proliferation and inhibited myoblast differentiation (Massague et ai, 1986) . When myoblasts differentiated spontaneously at high cell density the number of cellular receptors for TGF-ß was greatly reduced, a process also noted for EGF and FGF receptors (Ewton et ai, 1988) . Differentiation of tissues may therefore be associated with gross changes in growth factor responsiveness.
The myoblast model demonstrates that separate growth factors, which in the short term have similar mitogenic actions, can have opposite effects on long-term tissue phenotype, FGF blocking and IGF-I stimulating differentiation. Two observations suggest that IGFs are also involved in the differentiation of brain cell types. Firstly, when isolated cells from 1-day-old rat cerebellum were exposed to IGF-I glial cell differentiation was directed towards the production of oligodendrocytes rather than astrocytes (McMorris et ai, 1986) . Secondly, IGF-II synergized with nerve growth factor to promote neurite outgrowth from rat sensory and sympathetic ganglia (Recio-Pinto & Ishii, 1984). IGF-I has also been reported to potentiate the differentiation of fetal rat calvaría, chondrocytes, and erythroid precursor cells.
EGF modulates the differentiation of epithelial structures in the fetus and neonate. When administered to the fetal lamb for 2 weeks in the last third of pregnancy EGF caused hypertrophy of skin epithelium and the growth ofthe adrenal, thyroid, liver and kidney (Thorburn et ai, 1981) . In the fetal rabbit and lamb exogenous EGF induced lung epithelium maturation and surfactant production (Catterton et ai, 1979; Sundell et ai, 1980) , while in cultures of embryonic chick skin EGF inhibited glucocorticoid-induced epidermal keratinization (Obinata et ai, 1987) . Receptors for EGF are abundant in human placenta, especially on the microvillus plasma membranes in contact with the maternal circulation, and on the basolateral membranes adjacent to the fetal circulation (Roa et ai, 1984) . This distribution implies an interaction between EGF and the syncytiotrophoblast, and studies with isolated trophoblasts and placental cultures have shown that EGF modulates trophoblast differentiation and function. In homogeneous cultures of term trophoblasts, EGF caused a dose-related release of human placental lactogen and chorionic gonadotrophin (Morrish et ai, 1987) . There was no change in trophoblast cell number within these experiments but EGF induced a differentiation of cytotrophoblasts to form a syncytium. Parallel experiments with early and late placental expiants yielded similar results for hormone release (Maruo et ai, 1987 (Adashi et ai, 1988) . IGF-I was reported to stimulate directly granulosa cell proliferation, but not that of thecal cells (Hernandez et ai, 1988 (Adashi et ai, 1985; Veldhuis et ai, 1986) . The ability of IGF-I to enhance the appearance of LH receptors was augmented by oestrogens and/or thecal cell-derived andro¬ gens. In turn, IGF-I was reported to increase basal and LH-stimulated androstenedione release by thecal cells. On isolated porcine granulosa cells IGF-I increased granulosa cell differentiated function without the presence of FSH (Veldhuis et al., 1986) .
Thecal-interstitial cells within the follicle release TGF-ß (Skinner et ai, 1987) , which has little action on granulosa cell proliferation but, like IGF-I, synergizes with FSH to increase LH receptor number and steroidogenesis by granulosa cells (Knecht et ai, 1987) . These actions are attenuated by FGF. A molecule which is structurally related to TGF-ß is inhibin which is reported to be released from granulosa cells under FSH control and to block steroidogenesis by these cells (Hillier et ai, 1987; Bicsak et al., 1988) . The FSH-stimulated release of inhibin was potentiated by IGF-I, oestradiol and androstenedione, but blocked by EGF, or its analogue TGF-, which is expressed by the thecal-interstitial cells (Kudlow et ai, 1987) . EGF stimulated granulosa cell proliferation in most species examined except rat, and this action was suppressed by FSH. While some species variation exists, EGF generally blocked FSH-stimulated granulosa cell differentiation (Franchimont et ai, 1986) . Partly pure preparations of PDGF were reported to enhance granulosa cell proliferation and differentiated function but the physiological presence of PDGF in ovary is uncer¬ tain. Peptide growth factors have been implicated in the maturation of the rat oocyte, assessed by the breakdown of nuclear germinal vesicles as a marker of meiotic re-activation. TGF-ß caused an acceleration of maturation in follicle-enclosed oocytes and cumulus-oocyte complexes (Feng et ai, 1988) . This action was probably indirect since TGF-ß had no influence on cumulus-free oocytes.
IGF-I and -II also stimulated oocyte maturation while PDGF and insulin had no effect. (Morera et ai, 1987 (Deuel et ai, 1987) . At higher concentrations PDGF activated Superoxide generation, specific granule release and mobilization of calcium stores by neutrophils and monocytes. Such mobilizing actions of PDGF on inflammatory cells are reinforced by TGF-ß, which when included in wound chambers implanted into rats exerted chemoattractant properties for neutrophils, monocytes and fibroblasts (Sporn et ai, 1983) . Monocytes and macrophages are further potential sources of PDGF, TGF-ß and FGF release.
Chemoattraction may therefore lead to extremely high local concentrations of several growth factors at injury sites. When coupled with an abundant presence of IGFs derived from the circu¬ lation this may create an optimal synergistic interaction of growth factors necessary to initiate mesenchymal and epithelial proliferation and promote wound healing. In addition, TGF-ß pro¬ moted the synthesis of collagene and fibronectin, creating fresh extracellular matrix (Ignotz et ai, 1987) . Ectopie application of EGF in saliva could potentiate epithelial regeneration. Once the vascular endothelium is again intact platelet lysis will cease, the chemoattraction of inflammatory cells will decrease and the tissue growth factor presence will return to equilibrium. Support for such a model of wound healing is provided by the ability of exogenous, PDGF, TGF-ß or EGF/TGF-a to reduce wound healing time and increase the tensile strength of new tissue (Roberts et ai, 1986; Lynch et ai, 1987; Mustoe et ai, 1987; Schultz et ai, 1987 
